TCGA-43-6647-01A-11R-1820-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.660
- ANGIOGENESIS+0.540
- HEDGEHOG_SIGNALING+0.520
- TNFA_SIGNALING_VIA_NFKB+0.520
- IL6_JAK_STAT3_SIGNALING+0.480
- INFLAMMATORY_RESPONSE+0.480
- APICAL_JUNCTION+0.450
- UV_RESPONSE_DN+0.430
- HYPOXIA+0.400
- IL2_STAT5_SIGNALING+0.390
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.410
- E2F_TARGETS-0.310
- FATTY_ACID_METABOLISM-0.310
- MYC_TARGETS_V1-0.300
- DNA_REPAIR-0.240
- MYC_TARGETS_V2-0.240
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.180
- G2M_CHECKPOINT-0.130
- PANCREAS_BETA_CELLS-0.120
- PEROXISOME-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-A1AF-01A-11R-A13Y-07 | — | — | 0.915 |
| 2 | TCGA-AN-A0XN-01A-21R-A109-07 | — | A | 0.911 |
| 3 | TCGA-BH-A0BR-01A-21R-A115-07 | — | C | 0.894 |
| 4 | TCGA-60-2704-01A-11R-2045-07 | — | cohortSQ1 | 0.892 |
| 5 | TCGA-46-3767-01A-01R-0980-07 | — | cohortSQ1 | 0.888 |
| 6 | X17a4d870.71ef.4580.91db.071219517f26 | — | cohortSQ1 | 0.887 |
| 7 | SRR1516079 | — | — | 0.886 |
| 8 | TCGA-22-4609-01A-21R-2125-07 | — | cohortSQ1 | 0.885 |
| 9 | TCGA-64-5815-01A-01R-1628-07 | — | cohortA1 | 0.884 |
| 10 | TCGA-64-1679-01A-21R-2066-07 | — | cohortA1 | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.660 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.540 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.520 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.520 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.480 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.480 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.450 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.430 | Inavolisib | — uncovered |
| HYPOXIA | 0.400 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.390 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.390 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.360 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.350 | Inavolisib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.340 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.330 | Inavolisib | — uncovered |
| APOPTOSIS | 0.310 | Idelalisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |